Lack of correlation of functional scintigraphy with (99m)technetium-methoxyisobutylisonitrile with histological necrosis following induction chemotherapy or measures of P-glycoprotein expression in high-grade osteosarcoma.

In osteosarcoma, some studies have suggested P-glycoprotein expression is a prognostic factor. The clearance of (99m)technetium hexakis-2-methoxyisobutylisonitrile ((99m)Tc-MIBI) has been used in some tumor systems as an in vivo measure of P-glycoprotein-mediated efflux. In this study we explored the correlation between (99m)Tc-MIBI clearance and histological necrosis following induction chemotherapy and P-glycoprotein expression in osteosarcoma. The primary tumors of 20 patients with high-grade osteosarcoma were imaged at diagnosis with (99m)Tc-MIBI, and the uptake ratios and biological half-lives were calculated. P-Glycoprotein expression in the tumor tissue was determined immunohistochemically and by measuring mRNA expression of the multidrug resistance-1 gene. The histological necrosis following induction chemotherapy was assessed by the Huvos grading system. The biological half-life of (99m)Tc-MIBI ranged from 1.4 to 52.5 h. Seven of the 20 tumor samples had a favorable extent of necrosis following induction chemotherapy. The (99m)Tc-MIBI half-life and uptake ratio showed no correlation with histological necrosis following induction chemotherapy. The (99m)Tc-MIBI half-life and uptake ratio did not correlate with either measure of P-glycoprotein expression. The results of this pilot study indicate that (99m)Tc-MIBI imaging is not an effective predictor of histological necrosis following induction chemotherapy in high-grade osteosarcoma. (99m)Tc-MIBI imaging did not correlate with measures of P-glycoprotein expression in the tumor tissue.

[1]  P. D. Lee,et al.  MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Rastogi,et al.  Functional retention of Tc-99m MIBI in mediastinal lymphomas as a predictor of chemotherapeutic response demonstrated by consecutive thoracic SPECT imaging. , 1998, Clinical nuclear medicine.

[3]  J. Taki,et al.  Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  T. Grogan,et al.  P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. , 1997, Journal of the National Cancer Institute.

[5]  A. Gazdar,et al.  Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[6]  T. Yen,et al.  Technetium‐99m methoxyisobutylisonitrile chest imaging of small cell lung carcinoma , 1998, Cancer.

[7]  E. Franssen,et al.  99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. , 1998, British Journal of Cancer.

[8]  S. Larson,et al.  Thallium‐201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma , 1997, Cancer.

[9]  T. Kubota,et al.  99mTc-MIBI scintigraphy as an indicator of the chemosensitivity of anthracyclines in patients with breast cancer. , 1998, Anticancer research.

[10]  A Ciarmiello,et al.  Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  K. Danenberg,et al.  Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. , 1992, Cancer research.

[12]  Costan,et al.  Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. , 1996, Cancer research.

[13]  H. Hollema,et al.  99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours. , 1999, Anticancer research.

[14]  A. Huvos,et al.  Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Jhanwar,et al.  Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  F. Atkins,et al.  Technetium-99m-sestamibi parathyroid scintigraphy: effect of P-glycoprotein, histology and tumor size on detectability. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  G. Rosen,et al.  Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy , 1982, Cancer.

[18]  H. Bom,et al.  Technetium-99m-MIBI uptake in small cell lung cancer. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  P. Picci,et al.  P‐glycoprotein expression in osteosarcoma: A basis for risk‐adapted adjuvant chemotherapy , 1999, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[20]  R. Kramer,et al.  Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. , 1993, Cancer research.

[21]  T. Fojo,et al.  Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  G Rosen,et al.  Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Archer,et al.  P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma. , 1998, British Journal of Cancer.

[24]  P. Picci,et al.  Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. , 1995, The New England journal of medicine.

[25]  H. Hollema,et al.  Tc-99m-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours , 1999 .

[26]  T. Visser,et al.  99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-Q12 in vitro and in vivo. , 1998, Nuclear medicine and biology.

[27]  M. Sasaki,et al.  Prediction of the chemosensitivity of lung cancer by 99mTc-hexakis-2-methoxyisobutyl isonitrile SPECT. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  Y. S. Kim,et al.  Tc-99m MIBI SPECT is useful for noninvasively predicting the presence of MDR1 gene-encoded P-glycoprotein in patients with hepatocellular carcinoma. , 1999, Clinical nuclear medicine.

[29]  T. Leitha,et al.  Is early sestamibi imaging in head and neck cancer affected by MDR status, p53 expression, or cell proliferation? , 1998, Nuclear medicine and biology.

[30]  S. Emri,et al.  Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  A. Huvos,et al.  Expression of HER2/erbB-2 correlates with survival in osteosarcoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  I. Andrulis,et al.  Correlation of p-glycoprotein detection by immunohistochemistry with mdr-1 mRNA levels in osteosarcomas. Pilot study. , 1995, Diagnostic molecular pathology (Print).